– Clontech Laboratories, Inc. Releases the SMARTer® Stranded RNA-Seq Kit
Mountain View, CA—October 21, 2013—Clontech Laboratories,
Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the launch
of the SMARTer
Stranded RNA-Seq Kit for strand-specific RNA-Seq from low-input RNA
samples. This kit integrates Illumina® library preparation with SMART™ cDNA
amplification to create indexed libraries in less than four hours and provides
high-quality stranded data, with greater than 99% accuracy in strand
Carol Lou, General Manager of Clontech Laboratories, Inc., observed
that “Clontech has already pushed the limits of RNA-Seq down to extremely low
inputs—for example, with our SMARTer Ultra Low RNA Kit for Illumina Sequencing.
Now, we are expanding the applications of SMART technology to include cDNA
synthesis that retains strand origination data. This strand information is
critical for analyzing antisense transcripts, noncoding RNAs, and closely
spaced and overlapping genes, particularly in eukaryotic organisms with
incompletely-annotated or un-annotated transcriptomes and in prokaryotic
organisms, which have very compact genomes.”
“The SMARTer Stranded RNA-Seq Kit provides close to 100% strand
specificity while maintaining low input sensitivity, and also offers a much
faster and simpler protocol than other RNA-Seq kits. RNA-Seq experiments are
now being done routinely, and by reducing protocol time to less than 4 hours and
increasing strand specificity to over 99%, we are enabling scientists to do
more experiments” noted Andrew Farmer, Vice President of Research and
Development at Clontech Laboratories, Inc.
The SMARTer Stranded RNA-Seq Kit combines Clontech’s
patented SMART (Switching Mechanism at 5’ End of RNA Template) technology for full-length cDNA synthesis with direct addition
of a PCR adaptor, and creates indexed libraries for Illumina® NGS platforms in under
4 hours. Although other stranded RNA-Seq kits are available, Clontech’s SMARTer
Stranded RNA-Seq Kit has significant advantages, including greater than 99%
accuracy in strand identification even with very low inputs of sample (100
pg–10 ng input RNA), and a simple protocol that can be completed in half a day.
By comparison, other commercially-available methods require one to two full
days of effort to prepare libraries for RNA-Seq.
The SMARTer Stranded RNA-Seq Kit is ideal for most RNA-Seq
applications, including antisense transcript and noncoding RNA identification,
and for identifying the source of overlapping reads, such as reads from closely
spaced or overlapping genes, from closely related genes, or from prokaryotic
organisms. Clontech plans to continue expanding the use of SMART technology for
NGS, particularly in areas where low sample input is a constraint or a
requirement. For more information about SMARTer solutions for RNA-Seq, please
About Clontech Laboratories
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc.,
develops, manufactures, and distributes a wide range of life science research
reagents under the Clontech® and Takara® brands. Key products include SMARTer
cDNA synthesis kits for a variety of samples and applications, including NGS;
high-performance qPCR and PCR reagents (including the TaKaRa Ex Taq®, TaKaRa
LA Taq®, Titanium®, and Advantage® enzymes); RT enzymes and SMART library
construction kits; the innovative In-Fusion® cloning system; Tet-based
inducible gene expression systems; Living Colors® fluorescent proteins and a
range of Macherey-Nagel nucleic acid purification tools. These and other
products support applications including NGS, gene discovery, regulation, and
function; protein expression and purification; RNAi and stem cell studies; and
plant and food research. For more information, visit www.clontech.com.
About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga,
Japan. As a world leader in biotechnology research and development, Takara Bio
was the first company to market PCR technology in Japan and is also the
developer of the RetroNectin® reagent, which is used as a world standard in
gene therapy protocols. In addition to providing research reagents and
equipment to the life science research market, Takara Bio has active research
and product development activities in the fields of gene and cell-based therapy
and agricultural biotechnology; and is committed to preventing disease and
improving the quality of life for all people through the use of biotechnology.
Through strategic alliances with other industry leaders, Takara Bio aims to
extend its reach around the world. More information is available at www.takara-bio.com.
A Takara Bio